Literature DB >> 29733231

Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region.

Mukta Agrawal1, Swarnlata Saraf2, Shailendra Saraf2,3, Sophia G Antimisiaris4,5, Nobuhito Hamano6, Shyh-Dar Li6, Mahavir Chougule7,8, Sunday A Shoyele9, Umesh Gupta10, Amit Alexander1.   

Abstract

INTRODUCTION: Brain is supposed to be the most complicated part of the body which is very far from the reach of drug moieties. The drug entry in to the brain region depends upon various factors, and among those, the blood-brain-barrier remains the most prominent one. This barrier restricts the entry of almost all the drug and most of the essential biological components like proteins, peptides, etc. and hinders treatment of the CNS disorders. Alzheimer Disease (AD) is one such brain disorder, more specifically a neurodegenerative disorder which primarily affects the older adults. AREAS COVERED: From solubility enhancement to targeted delivery, the nanoparticulate system became the answer for almost all the criticality related to drug delivery. Hence, nanoparticulate drug carrier system has been widely utilizing to remove the hurdles of brain drug delivery. Keeping this in mind, we have underlined the proficiencies of the nanocarrier systems which claim to improve the drug efficacy for the treatment of the AD. EXPERT OPINION: The nanotechnological approaches are highly exploited by the researchers to enhance the drug permeation across the BBB to improve its bioavailability and efficacy by protecting the drug from peripheral degradation. However, still in this area of drug targeting provides vast scope for discoveries towards the enhancement of drug efficacy through surface modifications, site specification, reduced toxicity of the nanocarrier system and so on.

Entities:  

Keywords:  Alzheimer; BBB; NLC; SLN; lactoferrin; nanotechnology

Mesh:

Substances:

Year:  2018        PMID: 29733231     DOI: 10.1080/17425247.2018.1471058

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  12 in total

Review 1.  Blood-brain barrier: emerging trends on transport models and new-age strategies for therapeutics intervention against neurological disorders.

Authors:  Hema Kumari Alajangi; Mandeep Kaur; Akanksha Sharma; Sumedh Rana; Shipali Thakur; Mary Chatterjee; Neha Singla; Pradeep Kumar Jaiswal; Gurpal Singh; Ravi Pratap Barnwal
Journal:  Mol Brain       Date:  2022-06-01       Impact factor: 4.399

2.  Involvement of α7nAChR in the Protective Effects of Genistein Against β-Amyloid-Induced Oxidative Stress in Neurons via a PI3K/Akt/Nrf2 Pathway-Related Mechanism.

Authors:  Jianbin Guo; Guoqing Yang; Yuqing He; Huiming Xu; Hong Fan; Jing An; Lingling Zhang; Rui Zhang; Guihua Cao; Dingjun Hao; Hao Yang
Journal:  Cell Mol Neurobiol       Date:  2020-11-19       Impact factor: 5.046

Review 3.  Lactoferrin as Immune-Enhancement Strategy for SARS-CoV-2 Infection in Alzheimer's Disease Patients.

Authors:  Fernando Bartolomé; Luigi Rosa; Piera Valenti; Francisco Lopera; Jesús Hernández-Gallego; José Luis Cantero; Gorka Orive; Eva Carro
Journal:  Front Immunol       Date:  2022-04-25       Impact factor: 8.786

4.  Nose-to-brain drug delivery approach: A key to easily accessing the brain for the treatment of Alzheimer's disease.

Authors:  Amit Alexander; Shailendra Saraf
Journal:  Neural Regen Res       Date:  2018-12       Impact factor: 5.135

Review 5.  Recent expansions of novel strategies towards the drug targeting into the brain.

Authors:  Amit Alexander; Mukta Agrawal; Ajaz Uddin; Sabahuddin Siddique; Ahmed M Shehata; Mahmoud A Shaker; Syed Ata Ur Rahman; Mohi Iqbal M Abdul; Mohamed A Shaker
Journal:  Int J Nanomedicine       Date:  2019-07-30

6.  Transferrin-Modified Osthole PEGylated Liposomes Travel the Blood-Brain Barrier and Mitigate Alzheimer's Disease-Related Pathology in APP/PS-1 Mice.

Authors:  Liang Kong; Xue-Tao Li; Ying-Nan Ni; Hong-He Xiao; Ying-Jia Yao; Yuan-Yuan Wang; Rui-Jun Ju; Hong-Yan Li; Jing-Jing Liu; Min Fu; Yu-Tong Wu; Jing-Xian Yang; Lan Cheng
Journal:  Int J Nanomedicine       Date:  2020-04-23

7.  The Clustering of mApoE Anti-Amyloidogenic Peptide on Nanoparticle Surface Does Not Alter Its Performance in Controlling Beta-Amyloid Aggregation.

Authors:  Roberta Corti; Alysia Cox; Valeria Cassina; Luca Nardo; Domenico Salerno; Claudia Adriana Marrano; Natalia Missana; Patrizia Andreozzi; Paulo Jacob Silva; Francesco Stellacci; Roberta Dal Magro; Francesca Re; Francesco Mantegazza
Journal:  Int J Mol Sci       Date:  2020-02-05       Impact factor: 5.923

Review 8.  Intranasal drug delivery: opportunities and toxicologic challenges during drug development.

Authors:  Lea-Adriana Keller; Olivia Merkel; Andreas Popp
Journal:  Drug Deliv Transl Res       Date:  2021-01-25       Impact factor: 4.617

Review 9.  Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage.

Authors:  Amy Corbin Farr; May P Xiong
Journal:  Mol Pharm       Date:  2020-10-09       Impact factor: 4.939

Review 10.  Nano Carrier Drug Delivery Systems for the Treatment of Neuropsychiatric Disorders: Advantages and Limitations.

Authors:  Yana Zorkina; Olga Abramova; Valeriya Ushakova; Anna Morozova; Eugene Zubkov; Marat Valikhov; Pavel Melnikov; Alexander Majouga; Vladimir Chekhonin
Journal:  Molecules       Date:  2020-11-13       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.